Linden Thomas Advisory Services LLC Boosts Stake in Astrana Health, Inc. (NASDAQ:ASTH)

Linden Thomas Advisory Services LLC increased its position in Astrana Health, Inc. (NASDAQ:ASTH) by 23.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,247 shares of the company’s stock after buying an additional 2,883 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Astrana Health were worth $481,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Principal Financial Group Inc. purchased a new stake in shares of Astrana Health in the third quarter worth about $13,383,000. Franklin Resources Inc. bought a new stake in Astrana Health during the third quarter worth approximately $1,187,000. Hohimer Wealth Management LLC bought a new stake in Astrana Health during the third quarter worth approximately $312,000. Geode Capital Management LLC bought a new stake in Astrana Health during the third quarter worth approximately $58,995,000. Finally, Barclays PLC bought a new stake in Astrana Health during the third quarter worth approximately $4,457,000. 52.77% of the stock is currently owned by hedge funds and other institutional investors.

Astrana Health Price Performance

Shares of ASTH opened at $37.10 on Monday. The business’s 50-day moving average is $36.68 and its two-hundred day moving average is $46.70. The company has a market capitalization of $2.09 billion, a P/E ratio of 28.54, a P/E/G ratio of 1.46 and a beta of 1.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. Astrana Health, Inc. has a fifty-two week low of $29.08 and a fifty-two week high of $63.20.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. The company had revenue of $478.71 million for the quarter, compared to the consensus estimate of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same period last year, the firm earned $0.47 EPS. Research analysts predict that Astrana Health, Inc. will post 1.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ASTH shares. TD Cowen started coverage on Astrana Health in a research note on Monday, October 14th. They set a “buy” rating and a $66.00 price objective on the stock. KeyCorp started coverage on Astrana Health in a research note on Friday, October 11th. They set a “sector weight” rating on the stock. Robert W. Baird boosted their price objective on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Macquarie raised Astrana Health to a “hold” rating in a research note on Monday, December 16th. Finally, BTIG Research upped their target price on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $63.67.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.